The University of Texas MD Anderson Cancer Center, Houston, TX
Jorge E. Cortes , Tim H. Brümmendorf , Carlo Gambacorti-Passerini , Richard E Clark , Eric Leip , Andrea Viqueira , Vamsi Kota , Michael W.N. Deininger
Background: Tyrosine kinase inhibitor therapy has been linked to cardiac and vascular events. Cardiac, vascular and hypertension treatment-emergent adverse events (TEAEs) with bosutinib or imatinib for newly diagnosed chronic phase chronic myeloid leukemia were analyzed. Methods: Patients (pts) who received ≥1 dose of bosutinib (n = 268) or imatinib (n = 265) 400 mg/d in the phase 3 BFORE trial were included. Prespecified MedDRA terms comprised the clusters of investigator assessed TEAEs. Exposure-adjusted TEAE rate was defined as the number of pts with TEAEs / total pt-yr (pt-yr = sum of total time to first TEAE for pts with TEAEs and treatment duration for pts without TEAEs). Results: After ≥36 mo follow-up, 65% vs 62% of pts in the bosutinib vs imatinib arm were still on treatment. Rates of TEAEs, treatment withdrawals and drug-related TEAEs in the clusters of interest were low in both arms (Table). The most common cardiac, vascular and hypertension TEAEs, respectively, were sinus bradycardia (2%), angina pectoris (3%) and hypertension (7%) vs prolonged QT (3%), peripheral coldness (1%) and hypertension (9%) with bosutinib vs imatinib; corresponding grade 3/4/5 TEAE rates in the respective clusters were 3%, 3% and 4% vs 1%, 0.4% and 4%. Hypertension was the only grade 3/4 TEAE occurring in ≥1% of pts in either arm (4% each); 1 grade 5 TEAE each was noted for bosutinib (cardiac failure) and imatinib (cerebrovascular accident). Exposure-adjusted rates of cardiac, vascular and hypertension TEAEs, respectively, were 0.04, 0.03 and 0.04 vs 0.03, 0.01 and 0.04 (grade 3/4/5 only: 0.01, 0.01 and 0.02 vs 0.01, 0.002 and 0.02) for bosutinib vs imatinib. Conclusions: Cardiac, vascular and hypertension TEAE rates were low with bosutinib and imatinib. A majority of TEAEs were low grade and few led to treatment withdrawal. Clinical trial information: NCT02130557
n (%) | Bosutinib (n = 268) | Imatinib (n = 265) |
---|---|---|
Any cardiac TEAE | 23 (9) | 17 (6) |
Led to withdrawal | 1 ( < 1) | 0 |
Drug-related | 7 (3) | 6 (2) |
Any vascular TEAE | 18 (7) | 8 (3) |
Led to withdrawal | 3 (1) | 1 ( < 1) |
Drug-related | 5 (2) | 0 |
Any hypertension TEAE | 22 (8) | 25 (9) |
Led to withdrawal | 0 | 0 |
Drug-related | 2 (1) | 5 (2) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Jorge E. Cortes
2021 ASCO Annual Meeting
First Author: Tim H. Brümmendorf
2018 ASCO Annual Meeting
First Author: Jorge E. Cortes
2021 ASCO Annual Meeting
First Author: Michael W Deininger